We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Acacia Pharma Group Plc | LSE:0PNT | London | Ordinary Share | GB00BYWF9Y76 | ACACIA PHARM ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMACPH Acacia Pharma Group plc: Notice of Annual General Meeting Cambridge, UK and Indianapolis, US -- 25 May 2021 Acacia Pharma Group plc ("Acacia Pharma", the "Company") (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that its annual general meeting of shareholders ("AGM") will be held at 2:00pm BST on Monday 28 June 2021 at the offices of Acacia Pharma Inc, 8440 Allison Pointe Boulevard, Suite 100, Indianapolis, IN 46250, United States. The formal notice convening the AGM (including agenda, information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting) together with the Form of Proxy, and the Company's Annual Report and Accounts for the year ended 31 December 2020, will be posted to shareholders today and are available from today on the Company's website www.acaciapharma.com in the Investors/Shareholder Meetings section and the Investors/Financial Reports section, respectively. Contacts Acacia Pharma Group plc International Media Mike Bolinder, CEO Mark Swallow, Frazer Hall, David Gary Gemignani, CFO Dible +44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson IR@acaciapharma.com +44 20 7638 9571 acaciapharma@citigatedewerogerson.com US Investors Media in Belgium and the Netherlands LifeSci Advisors Chris Van Raemdonck Irina Koffler +32 499 58 55 31 +1 917-734-7387 chrisvanraemdonck@telenet.be ikoffler@lifesciadvisors.com About Acacia Pharma Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV). BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market. APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy. Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH. Acacia Pharma Group plc The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom Company number 9759376 www.acaciapharma.com
(END) Dow Jones Newswires
May 25, 2021 12:00 ET (16:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Acacia Pharma Chart |
1 Month Acacia Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions